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Cost considerations in determining the 
affordability of adjuvant trastuzumab 
in breast cancer
To the Editor: Cost considerations in determining affordability are 
extremely important for the sustainable health policy of all countries. 
It is of utmost importance that applied cancer treatment would result 
in a significantly improved cure rate being the primary objective, or at 
least a meaningfully reduced recurrence rate. 
The proposition presented by Abratt,[1] that state institution and 
lower-level medical schemes should consider <6 months of trastuzumab 
adjuvant therapy, is not supported by any solid clinical evidence and, if 
implemented, would result in fruitless depletion of resources.
Two small trials included in the Cochrane analysis, to which his 
article refers, merely suggested possible efficacy of shortened time 
of treatment.[2] Both studies were conducted with different primary 
objectives, other than duration of treatment and its effectiveness. In 
addition: (i) the first one included only 42 patients and the effect on 
overall survival (OS) was not reported;[3] and  (ii) the 5-year update 
of the second trial (FinHer) demonstrated no statistical difference in 
metastatic recurrence and mortality between control and trastuzumab 
arms.[4]
The lack of effectiveness of 6 months’ therapy has been confirmed 
by the robust PHARE trial.[5]
The National Institute for Health and Care Excellence (NICE) UK, 
known for its rigorous approach to cost-effectiveness, approved 1 year 
of trastuzumab treatment as being appropriate for the cash-strapped 
National Health Service (NHS).[6]
Emerging 10-year follow-up BCIRG-006 data show that the 
addition of 12 months of trastuzumab therapy resulted in a 24 - 36% 
improvement in OS and a 24 - 36% reduction in recurrence rates, 
depending on the chemotherapy regimen used. Cardiac toxicity risk 
could be halved by the choice of a non-anthracycline chemotherapy 
regimen.[7]
When calculating any cost-effectiveness, the state should also look 
at the cost of education of persons affected by the disease, as well as 
their role in the much-required stabilisation of the South African 
community. 
Cost-effectiveness calculations should include savings resulting 
from cure and avoidance of further lines of treatment. It should also 
include costs incurred by state, funders, community and family for 
continuous care of affected patients, should their breast cancer relapse. 
Any other calculations are usually biased to the financial needs of 
relevant interest groups. 
Should we rather advocate the use of scarce resources to effectively 
treat patients with defined intermediate and high risk for mortality 
and recurrence, instead of wasting them on futile, 6-month and less 
trastuzumab treatment regimens, as suggested by the author of this 
clinical alert?
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Prof. Raymond Abratt responds: The original article[1] focused 
on cost considerations in determining the affordability of adjuvant 
trastuzumab. In the final section of the article, the clinical ethical 
principle was noted that ‘clinicians should provide the best 
treatment possible with available resources, provided there is 
evidence of benefit and the clinician is prepared to undertake the 
treatment.’
In a well-resourced environment, 12 months of trastuzumab 
should be offered to patients. However, for the vast majority of 
patients in South Africa (SA) this is not available and they receive no 
adjuvant trastuzumab treatment at all. An option which oncologists in 
SA may consider, is <12 months of adjuvant trastuzumab. 
In the PHARE trial,[2] 6 months of adjuvant trastuzumab was 
shown to be marginally less effective than the 12-months regimen 
in terms of disease-free survival (DFS). The 2-year DFS was 
93.8% (95% confidence interval (CI) 92.6 - 94.9) in the 12-month 
group and 91.1% (89.7 - 92.4) in the 6-month group. However, 
significantly more patients in the 12-month group experienced a 
cardiac event than did those in the 6-month group, 5.7% v. 1.9%, 
p<0.0001.  
So, the number needed to treat (NNT) to prevent 1 recurrence at 
2 years, by giving an extra 6 months of trastuzumab, is 100/(93.8 – 
91.1) = 37. The NNT to prevent 1 recurrence at 23 months is 16 when 
12 months of trastuzumab is compared with no treatment.[3] This 
suggests a diminishing return in benefit and decreasing value, that is 
outcome/cost,[4] with the additional 6 months of therapy.  
But toxicity increases with the additional 6 months of treatment. 
The number needed to harm (NNH) for an extra cardiac event is 100/
(5.7 – 1.9) = 26. It is therefore more likely that a patient will suffer a 
cardiac event than have a breast cancer event prevented with an extra 
6 months of trastuzumab. 
The drug cost for an additional 6 months of trastuzumab is 
ZAR205 000 per patient. The drug cost to prevent one recurrence 
in the treated population, as described in the PHARE study, for an 
NNT of 37 = ZAR7 585 000. This is not affordable for SA’s healthcare 
systems. Downstream differences in costs between 6 and 12 months 
of adjuvant trastuzumab are irrelevant to patients who do not receive 
the drug at all.
The study findings and drug costs indicate that the 6-month 
regimen is a sound option and will increase the number of patients 
who will have access to adjuvant trastuzumab within the budgetary 
constraints of SA’s healthcare systems. The 12-month regimen 
should not be regarded as the only acceptable option in SA. The view 
that it is preferable that patients receive no adjuvant trastuzumab 
treatment rather than 6 months of adjuvant trastuzumab does not 
serve the purpose of benefiting patients. 
Scientific questions and costs influence patient care globally. [5] 
We need to work with Pharma and others to reduce the price of 
treatment and also to clarify all the associated cost-to-benefit 
patients in different prognostic groups.[1] Our aim is to provide 
high-quality care to all patients within the necessary constraints 
of cost.
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